SavedAdd your journal

Journals / Şişli Etfal Hastanesi Tıp Bülteni / 2019 / Cilt: 53 - Sayı: 2

Approach to Patients with Malignant Melanoma of Unknown Primary Origin

Selami Serhat SİRVAN
Hikmet İhsan EREN
Sevgi KURT YAZAR
Ali Can GÜNENÇ
Ayşin KARASOY YEŞİLADA
Fatih IRMAK
Deniz TUNCEL
Pages
125–131
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

As regards to the melanoma subtypes, nodular type in 45 patients, acral lentiginous type in 43 patients, superficial spreading type in63 patients, lentigo maligna melanoma in 15 patients, subungual type in 7 patients, and either unidentified melanoma or othersubtypes in 10 patients were identified.Conclusion: The ideal treatment of a patient with melanoma is multidisciplinary, with plastic surgery having a central role.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objectives: Although malignant melanoma accounts for 3% of skin cancers, it is responsible for 75% of deaths associated withskin cancer.
📊
Key Findings & Data:In our study, all melanoma cases diagnosed and treated at our clinic were retrospectively reviewed, and the cases ofunknown primary origin among them were examined in detail in terms of diagnosis and treatment.Methods: The patients with malignant melanoma treated at the inpatient services of our clinic between January 1991 and April2017 were retrospectively screened in the records.
💡
Conclusion & Impact:As regards to the melanoma subtypes, nodular type in 45 patients, acral lentiginous type in 43 patients, superficial spreading type in63 patients, lentigo maligna melanoma in 15 patients, subungual type in 7 patients, and either unidentified melanoma or othersubtypes in 10 patients were identified.Conclusion: The ideal treatment of a patient with melanoma is multidisciplinary, with plastic surgery having a central role.
🔬Design:Review & Systematic Survey
📍Scope:2017 Verileri
⚙️Variables:Domain Parameters

Özet

Objectives: Although malignant melanoma accounts for 3% of skin cancers, it is responsible for 75% of deaths associated withskin cancer. In our study, all melanoma cases diagnosed and treated at our clinic were retrospectively reviewed, and the cases ofunknown primary origin among them were examined in detail in terms of diagnosis and treatment.Methods: The patients with malignant melanoma treated at the inpatient services of our clinic between January 1991 and April2017 were retrospectively screened in the records. These patients were evaluated for age, sex, tumor type, Breslow depth, metastasis, and treatment. Among these patients, four cases of unknown primary origin were examined in detail.Results: During January 1991 and April 2017, 173 patients received inpatient care for malignant melanoma at our clinic. As regards to the melanoma subtypes, nodular type in 45 patients, acral lentiginous type in 43 patients, superficial spreading type in63 patients, lentigo maligna melanoma in 15 patients, subungual type in 7 patients, and either unidentified melanoma or othersubtypes in 10 patients were identified.Conclusion: The ideal treatment of a patient with melanoma is multidisciplinary, with plastic surgery having a central role.

🔖

Cite This Article

SİRVAN, S. S., EREN, H. İ., YAZAR, S. K., GÜNENÇ, A. C., YEŞİLADA, A. K., IRMAK, F., TUNCEL, D. (2019). Approach to Patients with Malignant Melanoma of Unknown Primary Origin. Şişli Etfal Hastanesi Tıp Bülteni, Cilt: 53 - Sayı: 2, 125–131. https://ajindex.com/articles/364010

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (15)

  1. Dzwierzynski WW. Managing malignant melanoma. Plast Reconstr Surg 2013;132:446e–60e
  2. Lasithiotakis KG, Leiter U, Gorkievicz R, Eigentler T, Breuninger H, Metzler G, et al. The incidence and mortality of cutaneous melanoma in Southern Germany: trends by anatomic site and pathologic characteristics, 1976 to 2003. Cancer 2006;107:1331–9
  3. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Murray T, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71–96
  4. Pavri SN, Clune J, Ariyan S, Narayan D. Malignant Melanoma: Beyond the Basics. Plast Reconstr Surg 2016;138:330e–40e
  5. Skarbez K, Fanciullo L. Metastatic melanoma from unknown primary presenting as dorsal midbrain syndrome. Optom Vis Sci 2012;89:e112–7
  6. Jaukovic L, Sijan G, Rajović M, Kandolf-Sekulovic L, Radulovic M, Mijuskovic Z, et al. Lymphoscintigraphy and sentinel lymph node biopsy, in cutaneous melanoma staging and treatment decisions. Hell J Nucl Med 2015;18:146–51
  7. Karasoy AK, Irmak F, Sevim KZ, et al. The case of malignant melanoma with extensive local recurrence and in-transit metastasis in the lower extremity. Turk Plast Surg 2012:3:39–42 8. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics, 2010. CA Cancer J Clin 2010;60:277–300
  8. Edwards BK, Brown ML, Wingo PA, Howe HL, Ward E, Ries LA, et al. Annual report to the nation on the status of cancer, 1975-2002, featuring population-based trends in cancer treatment. J Natl Cancer Inst 2005;97:1407–27
  9. Zbytek B, Carlson JA, Granese J, Ross J, Mihm MC Jr, Slominski A. Current concepts of metastasis in melanoma. Expert Rev Dermatol 2008;3:569–85
  10. Meier F, Will S, Ellwanger U, Schlagenhauff B, Schittek B, Rassner G, et al. Metastatic pathways and time courses in the orderly pro-gression of cutaneous melanoma. Br J Dermatol 2002;147:62–70
  11. Abeloff, MD. Clinical Oncology. 3rd ed. PA, Elsevier Churchill Livingstone; 2004
  12. Soong SJ, Harrison RA, McCarthy WH, Urist MM, Balch CM. Factors affecting survival following local, regional, or distant recurrence from localized melanoma. J Surg Oncol 1998;67:228–33
  13. Pack GT, Gerber DM, Scharnagel IM. End results in the treatment of malignant melanoma; a report of 1190 cases. Ann Surg 1952;136:905–11
  14. Dasgupta T, Bowden L, Berg JW. Malignant Melanoma of Unknown Primary Origin. Surg Gynecol Obstet 1963;117:341–5
  15. Anbari KK, Schuchter LM, Bucky LP, Mick R, Synnestvedt M, Guerry D 4th, et al. Melanoma of unknown primary site: presentation, treatment, and prognosis--a single inst